Singapore markets closed

Aligos Therapeutics, Inc. (ALGS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.8161-0.0299 (-3.53%)
As of 10:54AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 62.05M
Enterprise value -62.52M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.39
Price/book (mrq)0.67
Enterprise value/revenue -4.03
Enterprise value/EBITDA 0.74

Trading information

Stock price history

Beta (5Y monthly) 2.34
52-week change 3-31.77%
S&P500 52-week change 322.43%
52-week high 31.3400
52-week low 30.5390
50-day moving average 30.9143
200-day moving average 30.7918

Share statistics

Avg vol (3-month) 3402.23k
Avg vol (10-day) 3232.61k
Shares outstanding 572.58M
Implied shares outstanding 675.67M
Float 837.9M
% held by insiders 120.39%
% held by institutions 160.53%
Shares short (15 Apr 2024) 4657.21k
Short ratio (15 Apr 2024) 41.68
Short % of float (15 Apr 2024) 40.96%
Short % of shares outstanding (15 Apr 2024) 40.87%
Shares short (prior month 15 Mar 2024) 4365.6k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-942.67%

Management effectiveness

Return on assets (ttm)-36.63%
Return on equity (ttm)-89.48%

Income statement

Revenue (ttm)15.53M
Revenue per share (ttm)0.24
Quarterly revenue growth (yoy)-24.20%
Gross profit (ttm)N/A
EBITDA -85.84M
Net income avi to common (ttm)-87.68M
Diluted EPS (ttm)-1.3600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)135.7M
Total cash per share (mrq)1.79
Total debt (mrq)11.14M
Total debt/equity (mrq)12.10%
Current ratio (mrq)5.90
Book value per share (mrq)1.23

Cash flow statement

Operating cash flow (ttm)-79M
Levered free cash flow (ttm)-45.91M